Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data

  title={Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data},
  author={Levin Thomas and Sumit Birangal and Rajdeep Ray and Sonal Sekhar Miraj and Murali Munisamy and Muralidhar Varma and Chidananda Sanju S.V. and Mithu Banerjee and Gautham G. Shenoy and Mahadev Rao},
  journal={Therapeutic Advances in Drug Safety},
Introduction: Tuberculosis is a major respiratory disease globally with a higher prevalence in Asian and African countries than rest of the world. With a larger population of tuberculosis patients anticipated to be co-infected with COVID-19 infection, an ongoing pandemic, identifying, preventing and managing drug–drug interactions is inevitable for maximizing patient benefits for the current repurposed COVID-19 and antitubercular drugs. Methods: We assessed the potential drug–drug interactions… 

COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein

This review evaluated the interaction of current COVID-19 drugs with two ATP-binding cassette transporters [P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)] and potential drug-drug interactions (DDIs) among COVID -19 drugs, especially those associated with P-gp and BCRP efflux transporter.

In silico Approach to Identify Potent Bioactive Compounds as Inhibitors against the Enoyl-acyl Carrier Protein (acp) Reductase Enzyme of Mycobacterium tuberculosis

The anti-mycobacterial ability of triazole scaffolding in a new therapeutic was determined and compound CHEMBL441373 was shown to have the highest acceptable docking energy, making it a good candidate for a cell wall protein inhibitor (4U0J) that should be investigated further in vivo and in vitro.

COVID-19 and Pulmonary Tuberculosis Coinfection in a Moroccan Patient with Pulmonary Embolism: A Case Report and Literature Review

A sixty-seven-year-old male patient who was admitted to the CO VID-19 emergency department with a diagnosis of COVID-19 pneumonia is presented, confirmed by nasopharyngeal swab's polymerase chain reaction (PCR) for detection of SARS-CoV-2 and the atypical radiological findings suggested a TB coinfection.



Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review

Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety.

Drug repurposing approach to fight COVID-19

The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective.

Drug–drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain

Both comorbidities and polypharmacy were found as risk factors independently associated with DDIs development in hospitalized patients with confirmed SARS-CoV-2 infection.

High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment

A high frequency of DDI between LPV-r for treating COVID-19 and concomitant medications was found, including major DDI, which showed worse outcomes, but this association was explained by the older age and comorbidities.

Comparative Study of the Effects of Antituberculosis Drugs and Antiretroviral Drugs on Cytochrome P450 3A4 and P-Glycoprotein

  • Y. HoritaN. Doi
  • Biology, Medicine
    Antimicrobial Agents and Chemotherapy
  • 2014
Almost all the compounds showed the expected effects on human CYP3A4 both in the in vitro screening and in HepaRG cells, and the unproven mechanisms of DDIs caused by WHO group 5 drugs, thioamides, and p-aminosalicylic acid were elucidated.

Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

Given the high risk of cardiotoxicity and the scant and conflicting data concerning their efficacy in treating SARS-CoV-2 infection, the use of lopinavir/ritonavir and hydroxychloroquine in patients with COVID-19 with polypharmacy needs to be carefully considered.

A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness

Lexi-Interact and Micromedex showed the best performances in the ability of five common DDI programs to detect clinically important DDIs, and provided the most competent, complete, and user-friendly applications.